2. Table of Content
• Introduction
• History
• Strategy
• Key facts and figures
• Sanofi Management System (SMS)
• Conclusion
3. Introduction
• Sanofi is a French multinational pharmaceutical company headquartered in Paris,
France
• As from 2014, it is known as the world's forth-largest pharmaceutical company by
prescription sales.
• Logo: Motto:
• Sanofi engages in the
– research and development,
– manufacturing and marketing of pharmaceutical drugs principally in the prescription market,
– but the firm also develops over-the-counter medication.
4. • The company covers seven major therapeutic areas:
– Cardiovascular,
– central nervous system,
– diabetes,
– internal medicine,
– oncology,
– thrombosis
– and vaccines (it is the world's largest producer of the latter through
its subsidiary Sanofi Pasteur)
Introduction
5. • This company is a complex of individual companies that
have been merged together.
• Back in 1999, Sanofi was the second largest
pharmaceutical in France and number seven in Europe
according to the 1999 annual report.
History
Aventis
(1999)
Sanofi
(1973)-
Synthelabo
(1970)
[1999]
Sanofi-
Aventis
(2004)
Sanofi
(2011)
6. • The merger of pharmaceuticals is quite common in the sector.
• It came as a response to new competition and a change in the
healthcare sector where margins are cut.
• The company experienced internal and external challenges inherent in
this complex environment due to the introduction of generic
competitors.
• Therefore, the company has changed its government structure. The
long-prepared separation of the office of Chairman of the Board of
Directors and Chief Executive Officer assured continuity in the
strategy, dynamism and culture of sanofi-aventis
History
7. • The Company is managed by a Board of Directors composed of 14
members, 10 of whom are independent (a Director who has no relation
whatsoever with the company, its group or its management which may
impede his freedom of decision.)
• Members of our Board of Directors are appointed for a maximum term of four
years; reappointment of Directors is on a rotation basis
• In this way the company is following the global corporate governance "best-
practice”.
• The company has a strong and increasing presence in the BRIC- countries
(Brasil, Russia, India and China), but about 70% of the sales is achieved in
Europe and the US.
History
17. Sanofi Management System
(SMS)
SMS is a foundation for
industrial excellence, it uses a
strategic vision and ambition
to make Sanofi the gold-
standard for pharmaceutical
industry
18. Sanofi Management System
(SMS)
• Present in many countries to ensure patients and customers satisfaction
• Employs people to assist in proper health distribution
• Provides a large range of expertise and know-how for development of new
drugs from production to distribution
• Work towards achieving a gold standard in the pharmaceutical industry
• Build fundamentals with no compromise
24. Conclusion
• Acting ethically and responsibly enables Sanofi to go beyond what is required
of a company, which means employees working to protect and promote access
to healthcare for the greatest number.
• Corporate Social Responsibility also means supporting the local communities
in the countries where we operate while also contributing to global health
through specific Research & Development programs and private/public
collaboration.
• By considering the method Sanofi follows, there are great chances for it to
climb the ladder to be part of the best three pharmaceutical industries worldwide.
25. • Research & Development, Available at:
http://en.sanofi.com/Images/15406_RD_Portfolio_Phase_II-I_2015-07-30.pdf,
http://en.sanofi.com/Images/15395_RD_Portfolio_Pipeline_2015-07-30.pdf and
http://en.sanofi.com/Images/15404_RD_Portfolio_Phase_III_2015-07-30.pdf
• Sanofi Pipeline, Available at: http://www.sanofi.co.uk/l/gb/en/layout.jsp?scat=E096581E-
095C-45A7-BA82-AD5417CFBB83
• Sanofi Website at http://www.sanofi.co.uk/l/gb/en/index.jsp
• Sanofi at a glance, 2015, Available at: www.lehub.sanofi.com/en
• Sanofi History, Available at: https://en.wikipedia.org/wiki/Sanofi#History,
http://en.sanofi.com/our_company/history/history.aspx and
http://ezinearticles.com/?Company-Profiles---Sanofi-Aventis&id=1173003
• Sanofi Slogan, Available at: http://www.textart.ru/advertising/slogans/health/pharmaceutical-
company-slogans.html
• CSR Sanofi, 2014 report and mid 2015 report
References
Notes de l'éditeur
Tritace® (ramipril)
Epilim® (sodium valproate) & Stilnox® (zolpidem)
Lantus® (insulin glargine), a long-acting human insulin analog, market leader for branded insulins (IMS source). Lantus® is available is more than 120 countries worldwide.
Toujeo® (Insulin glargine).
Apidra® (insulin glulisine) a rapid-acting human insulin analog.
Insuman®, a range of rapid- and intermediate-acting human insulins.
Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist.
Amaryl®/Amarel® (glimepiride), a sulfonylurea-class hypoglycemic.
Afrezza® (insulin human) is a rapid-acting, inhaled insulin. Only available in the United-States.
4.
First of all, Aventis was formed in 1999 by the merger of Rhône-Poulenc and the German company Hoechst AG in France
In 2004 this new company merged with Sanofi that itself had completed a merger with Synthelabo.
Since 2004 the company name is Sanofi-Aventis.
At the beginning of February 2015, the R&D pipeline contained 43 projects (excluding Life Cycle Management) and vaccine candidates in clinical development of which 14 are in Phase III or have been submitted to the regulatory authorities for approval.